Aeglea BioTherapeutics, Inc. (AGLE) Analysts See $-0.54 EPS; Halfords Group plc (LON:HFD) Had 6 Bulls

April 17, 2018 - By Winifred Garcia

Halfords Group plc (LON:HFD) Logo

Analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to report $-0.54 EPS on May, 8.They anticipate $0.07 EPS change or 14.89% from last quarter’s $-0.47 EPS. After having $-0.38 EPS previously, Aeglea BioTherapeutics, Inc.’s analysts see 42.11% EPS growth. The stock increased 5.74% or $0.5176 during the last trading session, reaching $9.5276. About 28,297 shares traded. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 26.34% since April 17, 2017 and is uptrending. It has outperformed by 14.79% the S&P500.

Among 18 analysts covering Halfords Group PLC (LON:HFD), 6 have Buy rating, 2 Sell and 10 Hold. Therefore 33% are positive. Halfords Group PLC had 170 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Halfords Group plc (LON:HFD) earned “Reduce” rating by Numis Securities on Monday, November 14. The firm has “Buy” rating by HSBC given on Tuesday, November 15. Haitong Securities maintained it with “Neutral” rating and GBX 333 target in Monday, November 14 report. Investec maintained it with “Buy” rating and GBX 460 target in Friday, March 4 report. The rating was maintained by Investec on Thursday, May 25 with “Buy”. The stock of Halfords Group plc (LON:HFD) has “Neutral” rating given on Friday, January 19 by JP Morgan. The rating was maintained by Liberum Capital with “Buy” on Monday, October 12. The rating was maintained by Investec on Monday, November 7 with “Buy”. Numis Securities downgraded the stock to “Hold” rating in Friday, January 19 report. The stock has “Sell” rating by Deutsche Bank on Friday, January 20. See Halfords Group plc (LON:HFD) latest ratings:

06/04/2018 Broker: Citigroup Rating: Buy Upgrade
23/03/2018 Broker: Liberum Capital Rating: Hold Maintain
19/01/2018 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 370.00 New Target: GBX 436.00 Upgrade
19/01/2018 Broker: Numis Securities Rating: Hold New Target: GBX 360.00 Downgrade
19/01/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 360.00 New Target: GBX 360.00 Maintain
19/01/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 340.00 New Target: GBX 340.00 Maintain
19/01/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 340.00 New Target: GBX 340.00 Maintain
02/01/2018 Broker: Deutsche Bank Rating: Hold Old Target: GBX 340.00 New Target: GBX 340.00 Maintain
20/12/2017 Broker: Peel Hunt Rating: Sell Old Target: GBX 325.00 New Target: GBX 325.00 Maintain
08/12/2017 Broker: Deutsche Bank Rating: Hold Old Target: GBX 295.00 New Target: GBX 340.00 Maintain

Among 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeglea BioTherapeutics had 4 analyst reports since May 2, 2016 according to SRatingsIntel. The stock of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) earned “Outperform” rating by Wells Fargo on Monday, May 2. The firm has “Buy” rating by UBS given on Monday, May 2. The rating was initiated by Needham with “Buy” on Monday, May 9. BMO Capital Markets initiated Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) on Monday, May 2 with “Outperform” rating.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company has market cap of $159.27 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood. It currently has negative earnings. The company's lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

The stock decreased 0.05% or GBX 0.2 during the last trading session, reaching GBX 363.6. About 429,264 shares traded. Halfords Group plc (LON:HFD) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Halfords Group plc, through its subsidiaries, retails automotive, leisure, and cycling products. The company has market cap of 713.14 million GBP. It operates in two divisions, Retail and Car Servicing. It has a 13.32 P/E ratio. The firm offers car parts, cycling products, technology products, kids products, and camping and leisure equipment; and car service, repair, and MOTs to retail and fleet customers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts